Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(33.3%)

Phase 2

2(33.3%)

Phase 1

2(33.3%)

6Total

N/A(2)

Phase 2(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07558733Phase 1Recruiting

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Role: lead

NCT05300048Phase 1Terminated

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Role: lead

NCT06463028Phase 2Recruiting

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Role: lead

NCT05078775Not ApplicableCompleted

Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer

Role: lead

NCT05275673Phase 2Terminated

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Role: lead

NCT05183295Not ApplicableWithdrawn

Medical Food for the Dietary Management of Metastatic Colorectal Cancer

Role: lead

All 6 trials loaded